Genetic Technologies's quarterly market cap
increased
from Dec. 2023 ($9.27 Mil) to Mar. 2024 ($10.68 Mil) but then
declined
from Mar. 2024 ($10.68 Mil) to Jun. 2024 ($6.25 Mil).
Genetic Technologies's annual market cap
declined
from Jun. 2022 ($19.08 Mil) to Jun. 2023 ($16.30 Mil) and
declined
from Jun. 2023 ($16.30 Mil) to Jun. 2024 ($6.25 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genetic Technologies's Enterprise Value for Today is $3.67 Mil.
Genetic Technologies Market Cap Historical Data
The historical data trend for Genetic Technologies's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genetic Technologies's Market Cap
For the Diagnostics & Research subindustry, Genetic Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genetic Technologies's Market Cap for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Technologies (LTS:0A4N) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genetic Technologies Market Cap Related Terms
Thank you for viewing the detailed overview of Genetic Technologies's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0A4N has been successfully added to your 